initial public offerings (IPOs) trading on American exchanges

Monday, June 23, 2014

Cerulean Pharma (CERU) began trading on the NASDAQ on 10 April 2014

Cerulean Pharma Inc. is a clinical-stage oncology-focused company applying its tumor targeting platform. The Company’s nanopharmaceutical product candidates consist of polymers that are linked to anti-cancer therapeutics, or payloads. Its lead product candidate, CRLX101, is in Phase II clinical development and has the potential to address cancer therapies. CRLX301, the second product candidate, is a nanopharmaceutical with docetaxel, a microtubule stabilizer, as its anti-cancer payload. The clinical development of CRLX101 is focused on cancer indications. A two-part Phase II open-label IST of CRLX101 is being conducted in patients with relapsed ovarian cancer. CRLX301 is designed to act as a tubulin inhibitor, capitalizes on its payload, docetaxel.


5th Floor, 840 Memorial Drive
United States

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin-6200.00%-285716.70%
Operating margin-6293.62%-264333.30%
EBITD margin--261050.00%
Return on average assets-125.13%-140.01%
Return on average equity--

No comments:

Post a Comment